Research programme: anti-CD8 imaging agents - ImaginAb/Eli Lilly

Drug Profile

Research programme: anti-CD8 imaging agents - ImaginAb/Eli Lilly

Alternative Names: IAB22M2C

Latest Information Update: 20 Sep 2016

Price : $50

At a glance

  • Originator ImaginAb Inc
  • Class Antibody diagnostics; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Graft-versus-host disease

Most Recent Events

  • 15 Sep 2016 Lonza and ImaginAb complete a development and clinical supply program for IAB22M2C
  • 15 Sep 2016 ImaginAb intends to file an IND application for IAB22M2C
  • 03 Nov 2015 Preclinical trials in Graft-versus-host disease (Diagnosis) in USA (IV) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top